Retatrutide
A$449
Retatrutide
A next-generation triple-receptor agonist that targets GLP-1, GIP, and glucagon receptors simultaneously. This multi-target approach offers comprehensive metabolic support beyond single-receptor peptides.
Commonly considered for
Appetite regulation
Metabolic rate support
Body composition optimisation
Blood sugar balance
Energy metabolism
How it works
Works by activating three key metabolic receptors: GLP-1 (appetite regulation), GIP (nutrient sensing), and glucagon (energy mobilisation). This synergistic action supports balanced metabolic function.
Typical Use
Typically administered once weekly via subcutaneous injection. Best used as part of a comprehensive approach including nutrition and exercise.
Storage
Store unopened pens refrigerated at 2–8°C. Opened/activated pens should be used within 28 days when kept refrigerated. Do not freeze. Keep away from direct sunlight.
Practitioner Review
This compound is supplied exclusively following a Zenith assessment, bloodwork panel, and practitioner sign-off. Every supply includes a protocol card and dosing guide.
Research context: Currently in Phase 3 clinical trials showing promising results for metabolic health markers.
Frequently asked
Typically administered once weekly via subcutaneous injection. Best used as part of a comprehensive approach including nutrition and exercise.
Works by activating three key metabolic receptors: GLP-1 (appetite regulation), GIP (nutrient sensing), and glucagon (energy mobilisation). This synergistic action supports balanced metabolic function.
Retatrutide is commonly used alongside NAD+, MOTS-c.
All Zenith compounds are supplied exclusively following assessment, bloodwork, and practitioner review.
Regulatory & safety information
Retatrutide is supplied subject to suitability assessment and applicable UAE regulatory requirements. Information provided is general and is not a substitute for professional medical advice, diagnosis or treatment.
Always consult a qualified healthcare professional before starting, changing or stopping any product, particularly if you are pregnant, breastfeeding, under 18, or managing a medical condition.
Why treatment isn't self-selected
Treatment decisions need context.
Selecting a treatment option is the starting point. What's clinically appropriate for you is determined by three things together.
Your bloodwork
Relevant biomarkers help identify which treatment options may be appropriate — and which should be avoided.
Your health history
Existing conditions, medications and goals are considered alongside your results, not in isolation.
Practitioner review
A licensed practitioner reviews every request before anything is approved, dosed or supplied.
Before you choose
Your bloodwork can change the conversation.
Recent bloodwork gives your practitioner more to work with — helping identify what may be appropriate, what should be avoided, and where a different option might be better suited to your results.
Already uploaded results? Your practitioner reviews them alongside any treatment request — no need to repeat information.
Optional at this stage. Required before final approval.
Ready to move forward?
Three ways to continue.
Upload your bloodwork
Already have recent results? Upload them so your practitioner can review your treatment request in context.
Purchase a blood test
No recent results? Order an at-home Zenith blood test to establish your baseline before choosing treatment.
Start your assessment
Begin the health assessment now — you can add bloodwork and treatment selections at any stage.
Purchase
Retatrutide
Supplied following assessment, bloodwork and practitioner review.
Price
A$449
Ready to start?
Complete an assessment and get access to Retatrutide through a tailored protocol.